ABBV stock forecast, quote, news & analysis

Key Takeaways

• ABBV stock declined -9.2% over the past 30 days from approximately $230 to $209, driven by healthcare sector pressures and potential U.S. drug tariffs.
• Over the past quarter, the stock fell -6.7% from around $224, reflecting post-earnings weakness despite beats on Q4 2025 results.
• Main factors include softness in the aesthetics business (e.g., Botox, Juvederm), ongoing Humira erosion, and broader market concerns over regulatory risks.
• Strong growth in immunology drugs Skyrizi and Rinvoq offset some declines, with 2026 guidance projecting 9.5% revenue growth.
• Recent volatility shows range-bound trading amid tariff talks and sector sell-offs.

AbbVie (ABBV) Company Overview and Market Position

AbbVie Inc. (ABBV) is a research-based biopharmaceutical company focused on developing and commercializing therapies for immunology, oncology, neuroscience, eye care, and aesthetics. Its core business model revolves around a diversified portfolio of blockbuster drugs, including immunology leaders Skyrizi (risankizumab) and Rinvoq (upadacitinib), which have driven growth post-Humira patent loss. In the competitive biopharma industry, AbbVie holds a strong position with a robust pipeline and high free cash flow supporting dividends and acquisitions. These fundamentals explain recent stock behavior: resilient growth from new products cushions Humira biosimilar competition, but exposure to aesthetics and regulatory risks amplifies sector headwinds.

AbbVie (ABBV) Stock Price Performance: Last 30 Days vs. Quarter

Over the last 30 days, ABBV stock dropped -9.2%, closing near $209 from around $230 on early March 6, 2026. The movement was volatile and trend-driven downward, with sharp declines in late March and early April amid sector pressures.

For the past quarter, the stock fell -6.7% from $223.93 on January 6, 2026, to the recent $208.84 close on April 2. Performance was range-bound initially, peaking near $236 mid-period before steady erosion, reflecting mixed earnings reactions and macro influences.

What Drove ABBV Stock Price in the Last 30 Days

The 30-day decline stemmed from healthcare sector sell-offs, with ABBV shares plummeting alongside peers like Bristol-Myers Squibb and Novavax amid tariff fears. Proposed U.S. tariffs up to 100% on branded drugs heightened regulatory risks for biopharma stocks. Aesthetics weakness persisted, as Juvederm lagged estimates while Botox showed modest improvement, pressuring margins. Post-Q4 earnings digestion revealed investor focus on filler softness despite overall beats. Sentiment shifted negative on these macro and sector-specific concerns, outweighing positive migraine study data.

What Drove ABBV Stock Performance Over the Last Quarter

The quarterly downtrend was influenced by Q4 2025 earnings reaction in early February, where shares fell despite revenue of $16.62 billion and adjusted EPS of $2.71 beating estimates. Investors fixated on aesthetics declines and Humira erosion nearing $16 billion since loss of exclusivity (LOE), overshadowing Skyrizi/Rinvoq's 40%+ growth to $26 billion annually. Broader macro conditions, including inflation and interest rate sensitivity in healthcare, added pressure. Institutional flows favored growth over value, with ABBV underperforming the S&P 500. Cumulative impact: immunology strength sustained but couldn't counter regulatory and competitive headwinds.

Trending AI Robots

Tickeron’s Trending AI Robots page showcases the platform's top-performing AI-driven trading bots from hundreds available, scanning thousands of tickers across strategies like trend-following, mean reversion, and momentum plays. These curated bots are selected based on recent performance metrics such as win rate, average return, and Sharpe ratio, varying by timeframe from intraday to long-term holds. Users gain insights into real-time bot activity, backtested results, and live trading signals tailored to volatile markets like biotech. Explore the page to discover bots potentially suited for ABBV's current trends and enhance your stock analysis.

ABBV Stock Forecast Drivers: What Investors Should Watch Next

Investors should monitor Q1 2026 earnings on April 29 for updates on Skyrizi/Rinvoq sales trajectories toward $31 billion combined target. Track aesthetics recovery, including Trenebot launch and promotional efforts amid ongoing softness. Regulatory developments on drug tariffs and pricing reforms could sway sentiment. Pipeline milestones in oncology, neuroscience (e.g., Vyalev), and obesity assets represent catalysts, alongside immunology label expansions. Macro trends like interest rates and healthcare demand will influence sector flows; risks include biosimilar competition and M&A (mergers and acquisitions) impacts on IPR&D expenses.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full Disclaimers and Limitations.